Going blockbuster hunting, Vas Narasimhan outlines vision for ‘pure-play’ Novartis

Amber Tong

Senior Editor

By the time 2023 is over, Novartis expects to be moving much lighter: It will have spun out its generics subsidiary Sandoz, completed layoffs of thousands of staffers worldwide and put in new internal structures for running the company.

And it will be ready to hunt for blockbusters.

CEO Vas Narasimhan underscored Novartis’ upcoming transformation into a “pure-play” company, reiterating across a series of calls — one with reporters, two with investors and analysts — that the new structure would boost its R&D productivity and sharpen its focus on big, new medicines.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Going blockbuster hunting, Vas Narasimhan outlines vision for ‘pure-play’ Novartis

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

Head of Regulated Labs Market Strategy

Benchling

San Francisco, CA, USA

The next generation of AI biotechs is here. Can they deliver on the hype?

Bristol Myers to shutter Bay Area cell therapy R&D facility as it eliminates jobs and costs

AbbVie beats first-quarter expectations, but Humira guidance leaves analysts confused

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag

Ophthalmic biotech raises $16.5M; Pfizer’s AI collaboration bears fruit

Go­ing block­buster hunt­ing, Vas Narasimhan out­lines vi­sion for ‘pure-play’ No­var­tis

Senior Editor

Unlock this article instantly by becoming a free subscriber.

more like this

Benchling

San Francisco, CA, USA

Going blockbuster hunting, Vas Narasimhan outlines vision for ‘pure-play’ Novartis